Matching articles for "Saphris"
Issue 1699 · April 1, 2024
Drugs for Bipolar Disorder

Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die…

Med Lett Drugs Ther. 2024 Apr 1; 66(1699):49-54 doi:10.58347/tml.2024.1699a
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Issue 1615 · January 11, 2021 Free
In Brief: An Asenapine Patch (Secuado) for Schizophrenia

A transdermal formulation of the second-generation (atypical) antipsychotic asenapine ( Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the…

Med Lett Drugs Ther. 2021 Jan 11; 63(1615):7-8
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine ( Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since 2009.
Issue 1603 · July 27, 2020
Lumateperone (Caplyta) for Schizophrenia

The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation…

Med Lett Drugs Ther. 2020 Jul 27; 62(1603):113-6
The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Issue 1510 · December 19, 2016
Drugs for Psychotic Disorders

Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs…

Med Lett Drugs Ther. 2016 Dec 19; 58(1510):160-4
Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs used for treatment of these disorders are listed in Table 2.
Issue 1501 · August 15, 2016
Drugs for Bipolar Disorder

Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the…

Med Lett Drugs Ther. 2016 Aug 15; 58(1501):103-6
Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the drugs and dosages recommended here have not been approved by the FDA for use in bipolar disorder.
Issue 1493 · April 25, 2016
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder

The FDA has approved cariprazine ( Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with…

Med Lett Drugs Ther. 2016 Apr 25; 58(1493):51-3
The FDA has approved cariprazine ( Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
Issue 1475 · August 17, 2015
Brexpiprazole (Rexulti) for Schizophrenia and Depression

The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole ( Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):116-8
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole ( Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify) , a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.
Issue 130 · June 1, 2013
Drugs for Psychiatric Disorders

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them…

Treat Guidel Med Lett. 2013 Jun; 11(130):53-64
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Issue 1358 · February 21, 2011
Lurasidone (Latuda) for Schizophrenia

The FDA has approved lurasidone ( Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.

Med Lett Drugs Ther. 2011 Feb 21; 53(1358):13-4
The FDA has approved lurasidone ( Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Issue 96 · August 1, 2010
Drugs for Psychotic Disorders

The antipsychotic drugs listed in Table 1 on the next page are more effective for treating the “positive symptoms” of schizophrenia (hallucinations and delusions) than the “negative symptoms” (apathy,…

Treat Guidel Med Lett. 2010 Aug; 8(96):61-4
The antipsychotic drugs listed in Table 1 on the next page are more effective for treating the “positive symptoms” of schizophrenia (hallucinations and delusions) than the “negative symptoms” (apathy, social withdrawal, and blunted affect). Some symptoms of schizophrenia and acute psychoses may improve rapidly after treatment with antipsychotic drugs, but chronic schizophrenia improves slowly over many weeks and some patients may continue to improve for months. Most patients with chronic schizophrenia require prolonged maintenance therapy, but the risk of tardive dyskinesia and adverse metabolic effects must be kept in mind.
Issue 93 · May 1, 2010
Drugs for Depression and Bipolar Disorder

Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and…

Treat Guidel Med Lett. 2010 May; 8(93):35-42
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective, poorly tolerated or cannot be used. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1332 · February 22, 2010
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic

The FDA has approved the marketing of iloperidone ( Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone ( Risperdal , and…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):13-4
The FDA has approved the marketing of iloperidone ( Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone ( Risperdal , and others).